BRAIN and NERVE－神経研究の進歩60巻2号

2008年02月発行

特集 がん治療と神経障害

抗がん薬と頭痛

著者： 濱田潤一¹

所属機関： ¹北里大学医学部神経内科学

ページ範囲：P.149 - P.155

文献概要

はじめに

　がんの治療においては外科的療法だけではなく，分子標的薬などの近年の化学療法用薬剤の発展や治療法の改良により，化学療法が治療の主体となることも多くなってきている。また，血液系の悪性腫瘍の治療に関しては従来と変わることなく化学療法が主たる治療法である。抗がん薬の単剤のみならず多剤の併用により，副作用も多彩となり臨床的に正確な評価が必要である。この治療経過で，悪性腫瘍の患者の治療過程で起こるさまざまな症状が，いかなる要因に由来するものかを明らかにして，適切な対処を行わなければならない。最も重要なことは，原疾患の進展もしくは原疾患に起因する身体状態の変化なのか，薬剤あるいは治療による症状かを鑑別することであろう。

参考文献

1) 国際頭痛学会・頭痛分類委員会（日本頭痛学会・国際頭痛分類普及委員会　訳): 国際頭痛分類第2版, 新訂増補日本語版. 医学書院, 東京, 2007

2) Plotkin SR, Wen PY: Neurologic complications of cancer therapy. Neurol Clin 21: 279-318, 2003

3) Sullivan KM, Storb R, Shulman HM, Shaw CM, Sperce A, et al: Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. Ann Intern Med 97: 182-189, 1982

4) Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, et al: A phase Ⅱ study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000

5) Robak T, Blonski JZ, Kasznicki M, Konopka L, Ceglarek B, et al: Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia: updated results of the multicentre study of 378 patients. Br J Haematol 108: 357-368, 2000

6) Cheson BD, Vena DA, Foss FM, Sorensen JM: Neurotoxicity of purine analogs: a review. J Clin Oncol 12: 2216-2228, 1994

7) Resar LM, Phillips PC, Kastan MB, Leventhal BG, Bowman PW, et al: Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 71: 117-123, 1993

8) Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanick S, Recht L, et al: A randomized controlled trial comparing intrathecal sustained- release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5: 3394-3402, 1999

9) Donehower RC: An overview of the clinical experience with hydroxyurea. Semin Oncol 19 (3 suppl 9): 11-19, 1992

10) Boogerd W, vd Sande JJ, Moffie D: Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51: 1277-1283, 1988

11) Yim YS, Mahoney DH Jr, Oshman DG: Hemaiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphoblastic leukemia. Cancer 67: 2058-2061, 1991

12) Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286-294, 1991

13) Cantarini MV, Macpherson MP, Marshall AL, Robinson AV, Bailey CJ: A phase Ⅰ study to determine the effect of tamoxifen on the pharmacokinetics of a single 250mg oral dose of gefitinib (IRESSA) in healthy male volunteers. Cancer Chemother Pharmacol 56: 557-563, 2005

14) Lyass O, Lossos A, Hubert A, Gips M, Peretz T: Cisplatin-induced non-convulsive encephalopathy. Anticancer Drugs 9: 100-104, 1998

15) Tfayli A, Hentschel P, Madajewicz S, Manzione J, Chowhan N, et al: Toxicities related to intraarterial infusion od cisplatin and etoposide in patients with brain tumors. J Neurooncol 42: 73-77, 1999

16) Macdonald DR: Neurologic complications of chemotherapy. Neurol Clin 9: 955-967, 1991

17) Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, et al: Neurotoxicity of interferon-α in melanoma therapy: results from a randomized controlled trial. Cancer 83: 482-489, 1998

18) Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 9: 694-704, 1991

19) Foran JM, Rohatiner AZS, Cunningham D, Popescu RA, Solel-Celigng P et al: European phase Ⅱ study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18: 317-324, 2000

20) Watanabe N, Takahashi T, Sugimoto N, TanakaY, Kurata M, et al: Excellent response of chemotherapy- resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab. Int J Clin Oncol 10: 357-361, 2005

21) Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogeneous leukemia. N Engl J Med 346: 645-652, 2002

22) Baselga J, Carbonell X, Castaneda-Soto N-J, Clemens M, Green M, et al: Phase Ⅱ study of efficacy, safety, and pharmacokinetics of trastuzumab monotherpy administered on a 3-weekly schedule. J Clin Oncol 23: 2162-2171, 2005

23) Sievers E, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, et al: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19: 3244-3254, 2001

24) Treish IM: Targeting leukemia cells with gemtuzumab ozogamicin. Cancer Pract 8: 254-257, 2000

25) Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, et al: Phase Ⅱ study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10: 5732-5740, 2004

26) Gijtenbeek JM, van den Bent MJ, Vecht CJ: Cyclosporine neurotoxicity: a review. J Neurol 246: 339-346, 1999

27) Rozen TD: Migraine headache: Immunosupressant therapy. Curr Treat Options Neurol 4: 395-401, 2002

28) Rozen TD, Wijdicks EF, Hay JE: Treatment- refractory cyclosporine-associated headache: relief with conversion to FK-506. Neurology 47: 1347, 1996

29) Singhal S, Mehta J, Desikan R, Ayers D, Robertson P, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1572, 1999

30) Bussel JB, Mukherjee R, Stone AJ: A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 66: 172-177, 2001

31) Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, et al: PhaseⅠ／Ⅱ study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 13: 1966-1974, 1995